Multimodal data collection in Alzheimer’s disease: Participant acceptance of various digital technologies employed in the MEDIA study

The rate of failed drug trials in Alzheimer’s disease (AD) remains high. Many conventional endpoints currently used to demonstrate success of clinical trials lack sensitivity to drug treatment effects and perform disparately across disease stages. These endpoints tend to be burdensome “single time‐point” assessments that are vulnerable to subjectivity and rater errors.